- Home
- Publications
- Publication Search
- Publication Details
Title
The changing landscape of biosimilars in rheumatology
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 6, Pages 974-982
Publisher
BMJ
Online
2016-03-09
DOI
10.1136/annrheumdis-2016-209166
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names
- (2015) Jingdong Chao et al. ADVANCES IN THERAPY
- The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries
- (2015) Ashok Jha et al. ADVANCES IN THERAPY
- SAT0152 A Randomised, Double-Blind, Phase III Study Comparing SB2, An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
- (2015) J.-Y. Choe et al. ANNALS OF THE RHEUMATIC DISEASES
- In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study
- (2015) Polina Putrik et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
- (2015) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
- (2015) Elena Nikiphorou et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Biosimilars for the management of rheumatoid arthritis: economic considerations
- (2015) László Gulácsi et al. Expert Review of Clinical Immunology
- A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
- (2015) Rajendrakumar H. Jani et al. International Journal of Rheumatic Diseases
- Japanese regulatory authority's perspective on biosimilars
- (2015) Sumimasa Nagai et al. LANCET ONCOLOGY
- Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
- (2015) Tsutomu Takeuchi et al. Modern Rheumatology
- Biosimilars in rheumatology: current perspectives and lessons learnt
- (2015) Thomas Dörner et al. Nature Reviews Rheumatology
- Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists
- (2015) Petra Baji et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2015) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Uptake of the First Biosimilar Infliximab since its Approval in South Korea
- (2015) Seoyoung C. Kim et al. Arthritis & Rheumatology
- Putting the value into biosimilar decision making
- (2014) Mirhelen Mendes de Abreu et al. AUTOIMMUNITY REVIEWS
- The challenge of indication extrapolation for infliximab biosimilars
- (2014) Brian G. Feagan et al. BIOLOGICALS
- Biosimilars: the science of extrapolation
- (2014) M. Weise et al. BLOOD
- Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database
- (2014) Paola M. Cutroneo et al. DRUG SAFETY
- Biosimilars entering the clinic without animal studies
- (2014) Leon AGJM van Aerts et al. mAbs
- Pharmacoeconomics of Cancer Therapies: Considerations With the Introduction of Biosimilars
- (2014) David Henry et al. SEMINARS IN ONCOLOGY
- Biosimilars to treat inflammatory arthritis: the challenge of proving identity
- (2013) Jonathan Kay et al. ANNALS OF THE RHEUMATIC DISEASES
- Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
- (2013) Polina Putrik et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Inequities in access to biologic and synthetic DMARDs across 46 European countries
- (2013) Polina Putrik et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases
- (2013) Niels S. Vermeer et al. DRUG SAFETY
- Biosimilars: how similar?
- (2013) V. Strand et al. INTERNAL MEDICINE JOURNAL
- Clinical experience with Zarzio® in Europe: what have we learned?
- (2013) Pere Gascón et al. SUPPORTIVE CARE IN CANCER
- Introduction of an Infliximab Biosimilar (CT-P13): A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland
- (2013) G. McCarthy et al. VALUE IN HEALTH
- Does Value Mean Quality? The Payer's Perspective
- (2013) Jennifer L. Malin Journal of Oncology Practice
- The role of biosimilars in the treatment of rheumatic diseases
- (2012) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Biosimilars: what clinicians should know
- (2012) M. Weise et al. BLOOD
- The safety of switching between therapeutic proteins
- (2012) Hans C Ebbers et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The economic pressures for biosimilar drug use in cancer medicine
- (2012) Paul Cornes Targeted Oncology
- Experience of reviewing the follow-on biologics including Somatropin and erythropoietin in Japan
- (2011) Teruyo Arato et al. BIOLOGICALS
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Clinical comparability and European biosimilar regulations
- (2010) Huub Schellekens et al. NATURE BIOTECHNOLOGY
- Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database
- (2009) T Sokka et al. ANNALS OF THE RHEUMATIC DISEASES
- Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
- (2009) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started